Risk factors

Unicycive Therapeutics (UNCY) risk factors

Item 1A of every Unicycive Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open UNCY in Gloomberb →
  • FY2025 10-K risk factors

    55 risks, 1 dropped, 8 reworded since the prior year. The filing reflects ongoing capital raising needs, Nasdaq listing maintenance, and internal controls improvements. A key manufacturing vendor issue caused an FDA Complete Response Letter and a 12-month NDA delay. Insider ownership concentration decreased from 63% to 39%.

    Filed Mar 30, 2026
  • FY2024 10-K risk factors

    56 risks. This company has no prior year risk filing and operates as an early-stage biopharmaceutical enterprise with 19 employees. Major risks center on raising capital, obtaining FDA approvals, and relying entirely on third-party manufacturers.

    Filed Mar 31, 2025